Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Pharmacokinetics
Interventions: midomafetamine; Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy
Interventions: Midazolam, PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy Volunteers
Interventions: Danicamtiv; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Hypertension, Cardiovascular Diseases
Interventions: Vinyasa Yoga; Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control); Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Study Participants
Interventions: UCB0599, Esomeprazole, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: Semaglutide J, Semaglutide C; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Cypress, California • Kansas City, Kansas

Conditions: Lung Cancer
Interventions: Lung MRI, Blood Draw; Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Venglustat; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: Repaglinide, Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Breast Cancer, Breast Neoplasms, Breast Adenocarcinoma
Interventions: MRI Studies, Patient Reported Outcomes; Diagnostic Test · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Montvale, New Jersey • Commack, New York • New York, New York

Conditions: Healthy Volunteers
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypoxemia, Desaturation of Blood
Interventions: RespirAct Step-Wise Normocapnia desaturation sequence, RespirAct Slope Normocapnia desaturation sequence, RespirAct Step-Wise Hypocapnia desaturation sequence, RespirAct Slope Hypocapnia desaturation sequence, ROBD Step-Wise desaturation sequence; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteer
Interventions: midazolam; CP-690,550 + midazolam, CP-690,550 + midazolam; midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Febuxostat XR 80 mg Capsule F1, Febuxostat XR 80 mg Capsule F2, Febuxostat XR 80 mg Capsule F3, Febuxostat XR 80 mg Capsule F4; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Myeloma
Interventions: melphalan, topotecan (TPT), Autologous Stem Cell Rescue; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pre-Eclampsia, Neurocognitive Dysfunction
Interventions: Neuroimaging Procedures, Neuropsychological Assessment Procedures; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain Cancer
Interventions: MRI perfusion and PET/CT scans; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Glioblastoma
Interventions: NICO Myriad and Tissue Preservation System (TPS); Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Hepatitis C
Interventions: filibuvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Migraine, Small Vessel Ischemic Disease, Multiple Sclerosis
Interventions: Brain Neuroimaging; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 59 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: Ibrutinib, IMBRUVICA; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
Interventions: Beta blocker; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: Codeine Sulfate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Food Effects on Bioavailability of MDMA in Healthy Volunteers

A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Remote Vinyasa Yoga Program for Heart Health

Isocaloric Navy-Bean Substitution in Adults With MASLD

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening

A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy

A Study of Soticlestat Tablets in Healthy Adults

Alternate Methodology of Pulse Oximeter Validation

CP-690,550 and Midazolam Drug-Drug Interaction Study

Phase 1, Febuxostat XR Relative Bioavailability Study

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

Changes in fMRI and Neurocognitive Function in Women With Pre-eclampsia

A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression

Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

A Study to Evaluate White Matter Hyperintensities in Migraine

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

A Preliminary Study for INFORMED

Dose Linearity Study of Codeine Sulfate Under Fasted Conditions